



Virta Health Reaches Profitability

Now serving more than 750 employers,
health plans, and government organizations

Virta attracts new long-term investment
and adds healthcare leadership to its board


For more than a decade, Virta
has challenged the status quo
with a fundamental idea:

Metabolic disease
is reversible.

In 2026 alone, **new peer-reviewed research expanded the evidence behind Virta's approach**, building on established outcomes beyond weight loss, type 2 diabetes reversal, and medication reduction.




Stage IV Pancreatic
Cancer Treatment




Chronic Inflammation



Liver Disease



Kidney Disease




Cardiovascular Disease

Members achieve

13%

Average weight loss at
one year without GLP-1s¹

Driven by **Metabolic Intelligence**,
Virta's AI-powered, clinician-supervised
system, delivers personalized guidance
that quickly adapts as a member's
health changes.



1. McKenzie and Athinarayanan, Diabetes Therapy (2024), never-GLP-1 T2D cohort

“We spent our first decade proving
what was possible. Now the market
is catching up to the opportunity.

We have stronger evidence, better technology, more experience,
and a stronger business than at any point in our history. We built
Virta for this moment, and it's still day one for us.”

Sami Inkinen
Co-Founder & CEO, Virta Health

Read more